CONTINUE TRUSTING 1L ALECENSA
FOR PATIENTS WITH ALK+ ADVANCED NSCLC

Not a real patient.

PROVEN
PROTECTION

Sustained clinically meaningful PFS1

mPFS: 34.8 months with ALECENSA vs 10.9 months with crizotinib

SUPERIOR
SURVIVAL

6 out of 10 patients are alive at
5 years1 OS rate: 62.5% with ALECENSA vs 45.5% with crizotinib; ALECENSA mOS yet to be reached 

REASSURING
EXPERIENCE

Sustained clinically meaningful improvement in quality of life2
5 month extension in HRQoL improvement vs crizotinib

Fast facts

~70%

of patients with ALK+ NSCLC have never smoked3–6

Fast facts

>50%

of patients with ALK+ NSCLC are younger than 60 years7

Fast facts

~30%

of patients with ALK+ NSCLC have baseline CNS METASTASES at diagnosis3,5,7

Fast facts

>50%

of patients with ALK+ ADVANCED NSCLC receiving crizotinib progress within 1 year1

Fast facts

>50%

of patients with ALK+ ADVANCED NSCLC receiving crizotinib will not live past 5 years1

1L: first line; ALK: anaplastic lymphoma kinase; HRQoL: health-related quality of life; mPFS: median progression-free survival; mOS: median overall survival; NSCLC: non small-cell lung cancer; OS: overall survival; PFS: progression-free survival; SmPC: Summary of Product Characteristics.

 

1. Mok T, et al. Ann Oncol 2020;31(8):1056–1064; 2. Pérol M, et al. Lung Cancer 2019;138:79–87; 3. Pacheco JM, et al. J Thorac Oncol 2019;14(4):691–700; 4. Du X, et al. Thorac Cancer 2018;9(4):423–430; 5. Patil T, et al. J Thorac Oncol 2018;13(11):1717–1726; 6. Gainor JF, et al. JCO Precis Oncol 2017;2017:PO.17.00063; 7. Johung KL, et al. J Clin Oncol 2016;34(2):123–129.